Confronting The Dilemmas Of Disruption
Source: Life Science Leader
By Scott D. Anthony
Disruptive forces are reconfiguring the biopharmaceutical industry. High profits mask fierce competition, political and reputational challenges, and unrelenting access and affordability pressures. Transformative technologies are enabling new competitors such as Apple, Google, and Nestle to edge into the market.
History teaches us that disruptive change is bad news for even the best-run incumbents. How can executives confront the dilemmas of disruption? The title of our recent book, Dual Transformation, provides our answer.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more